Drug review.Drug Review: The U.S. Food and Drug Administration has agreed to review an experimental drug to treat colon cancer created by Thousand Oaks-based biotechnology company Amgen. Called panitumumab, the antibody was submitted for the treatment of metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colorectal cancer in patients in which chemotherapy has failed. The drug interferes with the epidermal growth factor receptor This article is about a cell suface receptor. For estimated measure of kidney function (eGFR), see Glomerular filtration rate. The epidermal growth factor receptor of patients, affecting how cancer cells grow, mutate mu·tate intr. & tr.v. mu·tat·ed, mu·tat·ing, mu·tates To undergo or cause to undergo mutation. [Latin m and survive. It is being evaluated in clinical trials both by itself and in combination with other agents to treat a variety of cancers. The FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. gave Amgen priority review, a fast track reserved for applications that would make significant advancements over existing therapies. The designation means FDA action could come within six months, as opposed to the typical 10-month review process. Colorectal cancer is the third most common cancer diagnosed in the United States. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion